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Abstract
Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with multiple susceptibility genes. We
have previously reported suggestive linkage to the chromosomal region 14q21-q23 in Finnish SLE families.
Principal Findings: Genetic fine mapping of this region in the same family material, together with a large collection of
parent affected trios from UK and two independent case-control cohorts from Finland and Sweden, indicated that a novel
uncharacterized gene, MAMDC1 (MAM domain containing glycosylphosphatidylinositol anchor 2, also known as MDGA2,
MIM 611128), represents a putative susceptibility gene for SLE. In a combined analysis of the whole dataset, significant
evidence of association was detected for the MAMDC1 intronic single nucleotide polymorphisms (SNP) rs961616 (P –
value = 0.001, Odds Ratio (OR) = 1.292, 95% CI 1.103–1.513) and rs2297926 (P –value = 0.003, OR = 1.349, 95% CI 1.109–
1.640). By Northern blot, real-time PCR (qRT-PCR) and immunohistochemical (IHC) analyses, we show that MAMDC1 is
expressed in several tissues and cell types, and that the corresponding mRNA is up-regulated by the pro-inflammatory
cytokines tumour necrosis factor alpha (TNF-a) and interferon gamma (IFN-c) in THP-1 monocytes. Based on its homology to
known proteins with similar structure, MAMDC1 appears to be a novel member of the adhesion molecules of the
immunoglobulin superfamily (IgCAM), which is involved in cell adhesion, migration, and recruitment to inflammatory sites.
Remarkably, some IgCAMs have been shown to interact with ITGAM, the product of another SLE susceptibility gene recently
discovered in two independent genome wide association (GWA) scans.
Significance: Further studies focused on MAMDC1 and other molecules involved in these pathways might thus provide new
insight into the pathogenesis of SLE.
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Introduction
SLE (MIM152700) is a multisystemic autoimmune disorder,
with varying incidence and prevalence between populations [1].
The disease is characterized by autoantibody production against
self, formation of immune complexes, and subsequent tissue
inflammation in multiple organs such as the skin, joints, kidneys
and heart. Although the underlying pathogenic mechanisms of
SLE remain imperfectly understood, both environmental influ-
ences and genetic factors have been found to play an important
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role in disease initiation and progression [2–4]. Supporting a
genetic component in SLE, genome-wide linkage scans have
identified several loci showing significant linkage to the disease,
some of which have been confirmed in independent studies
(reviewed in [5–10]). In particular, the importance of the two
chromosomal regions 6p22.3–p21.1 (HLA region) and 16p12.3–
q12.2 has been highlighted in a meta-analysis of genome wide
linkage studies in SLE [11]. In addition to these loci, a large
number of genes and genetic effects have been associated to SLE
through candidate gene studies (reviewed in [5–9]). Recent GWA
studies have further provided new fundamental insight into the
genetics of SLE by identifying new susceptibility genes and
consolidating results obtained in previous studies [12–15].
Our group previously reported suggestive linkage on chromo-
somes 5p (Nonparametric linkage (NPL) score = 2.03, P-val-
ue = 0.02), 6q25-q27 (NPL score = 2.47, P-value= 0.008), 14q21-
q23 (NPL score = 2.20, P-value = 0.02) as well as the HLA region
(NPL score = 2.17, P-value = 0.02) in a genome-wide scan of 35
Finnish multiplex families [16]. Following up the loci on
chromosome 6q and 14q, with an additional 31 Finnish simplex
families included in the cohort, we identified sharing of two
common haplotypes on chromosome 14q21-23 (spanning markers
D14S978-D14S589-D14S562 and D14S1009-D14S748, P-value
= 0.006 and 0.14 respectively), and excess transmission of a
haplotype (GATA184A08-D6S1637, P-value = 0.07) on 6q [17].
The chromosome 14 region had previously been reported as a
suggestive SLE susceptibility locus in two other independent
studies [18,19] as well as in Systemic Sclerosis (MIM 181750) [20],
and was thus subsequently considered of particular interest for
gene identification.
In the present study, we have taken a hierarchical, multistep
approach to delineate the SLE susceptibility locus contained
within the chromosome 14q21-14q23 region and identified a gene,
MAMDC1, as a novel candidate gene for SLE.
Results
The original Finnish cohort, with an additional 126 families,
was used in the initial fine mapping, which focused on the two
regions showing haplotype sharing in the previous fine-mapping
[16,17]. This step of genotyping included 19 microsatellite (MS)
markers and 17 SNPs, located within a region spanning 14q11.2-
q23 (Figure 1 and Table S1). Together with the MS markers
already analyzed in our previous studies [16,17] genotyping data
were thus available in this initial step for 47 MS markers and 17
SNPs, corresponding to an average marker distance of 350 kilo
bases (kb) in the region. To increase the chances of identifying SLE
susceptibility loci in this region, two different statistical analyses
were performed on genotyped data; Pedigree Disequilibrium Test
(PDT) [21] and Haplotype Pattern Mining (HPM) [22]. As
graphically reported in Figure 1, only one region provided positive
signals of association with both methods, namely the 800 kb
sequence contained between markers D14S1068 and rs1955810.
The poorly characterized geneMAMDC1 maps right in the middle
of and are entirely contained within this region. We therefore
focused our downstream analysis onto this locus.
To further explore the observed association, three additional
SLE cohorts were included in the study; one family cohort from
the UK consisting of 365 SLE parent affected trios, one case
control cohort from Finland consisting of 86 SLE cases and 356
controls and one case control cohort from Sweden consisting of
304 SLE cases and 307 controls (see Material and methods and
Table S1). Twenty four SNPs, spanning the MAMDC1 gene, were
thus subsequently genotyped in all four sample populations to
obtain information regarding the genetic contribution of
MAMDC1 in the European population (Figure 1 and Table S1).
A combined analysis, including all four populations, revealed that
two SNPs at the MAMDC1 locus; rs961616 (P –value = 0.001,
OR=1.292, 95% CI 1.103–1.513) and rs2297926 (P – value
= 0.003, OR=1.349, 95% CI 1.109–1.640) significantly contrib-
ute to SLE susceptibility after correction for multiple testing. A
graphical view of the P – value distribution of the 24 markers is
shown in Figure 1 and exact values are shown in Table S2.
Haplotype analysis was also performed for each sample population
but this did not add any further information.
Despite some individual differences between the study popula-
tions, no significant findings were obtained by heterogeneity
testing, and the pooled ORs for rs961616 and rs2297926 both
remained above the threshold of significance (Figure 2), thus
suggesting MAMDC1 as a candidate gene in SLE susceptibility.
MAMDC1 is a poorly characterized gene spanning 835 kb of
DNA sequence on the reverse strand of Chromosome 14q21.3,
and predicted to be composed of two alternative first exons (1a and
1b) and 16 downstream exons giving rise to two mRNAs of similar
size (5375 bp for isoform 1, and 5239 bp for isoform 2,
respectively; Figure 3A). These correspond to MAMDC1 full-
length protein (956 amino acids [aa], Figure 3B) and a shorter
peptide where translation is predicted to start at an internal ATG
codon from exon 7 (727 aa, not shown). Strikingly, the former
shows .97% aa identity with chimpanzee, mouse, rat, dog and
horse MAMDC1 orthologs, suggesting an important function for
this highly conserved protein. As shown in Figure 3B, analysis of
human MAMDC1 full length amino acid sequence with the
protein prediction tool InterPro Scan [23] revealed the presence of
6 immunoglobulin (Ig) like domains, a fibronectin type III like
(FNIII) fold domain, and a meprin/A5-protein/PTPmu (MAM)
domain in the corresponding polypeptide chain. In addition, a C-
terminal GPI anchoring signal was detected using big-PI Predictor
[24], and an N-terminal signal sequence with SignalP [25].
Interestingly, identical domain structures are found in the human
homolog MDGA1 (MIM 609626) [26,27] and in the rat orthologs
MDGA1 and MDGA2 previously identified in different neuronal
populations [28]. Based on their protein architecture and pattern
of expression, MDGA proteins have been proposed as a novel
subgroup of the IgCAM super family, an important class of
membrane proteins involved in cell-cell adhesion, migration and
the development of neuronal connections [29]. An alignment of
MAMDC1 with these and other proteins sharing similar domains
and suggested to have a role in adhesion is reported in Figure 4.
In order to initially characterize MAMDC1 distribution in
different tissues and cells, we sought to analyze its mRNA and
protein expression patterns, respectively by Northern blot
hybridization and IHC experiments. As shown in Figure 5, a
weak signal corresponding to the expected MAMDC1 mRNA size
of 5 kb was seen in all tissues except urinary bladder and uterus
after hybridization of the full-length cDNA probe (corresponding
to MAMDC1 isoform 1) on two human multiple tissue polyA+
RNA Northern blots. Several additional transcripts of smaller size
were also present in tissues such as the brain, heart, pancreas and
others, while a band of approximately 9 kb was further seen in
brain, placenta and thyroid, thus suggesting that MAMDC1
primary transcript undergoes alternative splicing. Hence, our
results indicate that human MAMDC1 has a much broader
expression than its MDGA2 rat ortholog [28], as it is found at a
low level in a wide range of tissues outside the nervous system.
To confirm and extend these results, we then studied
MAMDC1 protein expression by IHC on formalin-fixed paraf-
fin-embedded tissue sections from testis, kidney, duodenum,
MAMDC1 and SLE Susceptibility
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Figure 1. Identification of MAMDC1 as the SLE susceptibility locus in the 14q21-q23 linkage region. Fine mapping towards the
identification of MAMDC1 was first performed in the original Finnish family cohort by genotyping 19 MS markers and 17 SNPs, focusing on the two
regions located on 14q11.2-q23 that showed haplotype sharing in the previous fine-mapping [16,17]. PDT and HPM analyses were used and regions
providing significant results (p#0.05) are shown in black and blue, respectively (top of the figure). The region between markers D14S1068 and
rs1955810, containing the gene MAMDC1, was selected for further fine mapping (highlighted in blue). Twenty-four SNPs were subsequently
genotyped in the whole sample material and as shown graphically in the figure, significant association for the SNPs rs961616 and rs2297926 could be
identified using a combined analysis (bottom of the figure). The significance threshold were set to P= 0.0032 (see the statistics section under material
and methods) and is represented by a red line.
doi:10.1371/journal.pone.0008037.g001
MAMDC1 and SLE Susceptibility
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Figure 2. Individual and pooled odds ratios for rs961616 and rs2297926. The individual and pooled contribution of each sample
population for rs961616 (A) and rs2297926 (B), shown as ORs.
doi:10.1371/journal.pone.0008037.g002
Figure 3. Human MAMDC1 gene, mRNA and protein structure. A) MAMDC1 genomic structure and exon-intron organization. Exons are
reported as plain boxes with relative length (in bp) below. Intronic intervening sequences are also shown with relative length (in kb) above. Two
alternative MAMDC1 mRNA isoforms are predicted to be transcribed from the MAMDC1 locus, corresponding to NCBI database entries
NM_001113498 and NM_182830. Translation initiation codons (ATG) are indicated for both isoforms. B) Schematic representation of MAMDC1
predicted full-length protein (corresponding to mRNA isoform 1), and its structural domains with relative length (amino acid positions) below.
doi:10.1371/journal.pone.0008037.g003
MAMDC1 and SLE Susceptibility
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placenta, cutaneous squamous cell carcinoma, and SLE skin. A
rabbit anti-MAMDC1 antibody was used for this purpose and as
shown in Figure 6, MAMDC1 protein expression could be
detected in Leydig cells of the testis, in placental syncytial
trophoblasts and epithelial cells of the duodenal villi (Figures 6A,
6C and 6D respectively). Further, both kidney and cutaneous
squamous cell carcinomas showed positive staining in neutrophils
(Figures 6E and 6I). In skin samples obtained from SLE patients
the protein was detected in elastic fibres in the upper layers of
dermis (Figures 6G and 6H). The results obtained with IHC are in
accordance with the data obtained from the analysis of mRNA
expression, and further support the finding that MAMDC1 is
expressed in tissues other than the nervous system.
We next sought to determine whether such expression shows
conditional regulation, and tested the effect of pro- and anti-
inflammatory stimuli on gene transcription in vitro. The cell lines
THP-1 (monocytic leukemia), A431 (epidermoid carcinoma),
A549 (lung epithelial carcinoma), HeLa (cervix epithelial adeno-
carcinoma), SH-Sy5y (neuroblastoma), MCF7 (breast adenocarci-
noma), HCT116 (colon carcinoma) and HEK293 (embryonic
kidney cells) were first tested for MAMDC1 mRNA expression in a
quantitative qRT-PCR assay specific for the full-length isoform 1.
In these experiments, moderate levels of MAMDC1 could be
detected in THP-1 and MCF7 cells, while all other cell-lines
showed little or no mRNA expression (data not shown).
Monocytes play a key role in inflammation and immunological
diseases, and therefore we selected the THP-1 monocytic cells for
the next experiments. The effect exerted on MAMDC1 mRNA
expression by TNF-a, IFN-c and interleukin 1 beta (IL-1b), three
cytokines playing a pivotal role in inflammation and in chronic
inflammatory diseases such as SLE [30–32], by lipopolysaccharide
(LPS), a potent endotoxin activating macrophage pro-inflamma-
tory responses, and by transforming growth factor beta 1 (TGF-
b1), an anti-inflammatory cytokine with pleiotropic effects in SLE
and other autoimmune disorders, was then determined by qRT-
PCR on THP-1 cells at 6 h and 24 h after the addition of these
molecules to the culture medium. While no differences were
observed 6 h post stimulation (not shown), an increase in
MAMDC1 mRNA levels was observed 24 h after the addition of
either TNF-a or IFN-c to THP-1 cells (2.5 and 2.4 fold induction,
respectively, Figure 7). Of note, such increase was dramatically
pronounced under the combined stimulus of these two cytokines
(63 fold induction), possibly due to their known synergistic pro-
inflammatory effect on gene transcription [33].
Discussion
In the present study, we have identified association between
SNPs in the novel gene MAMDC1 and SLE in four independent
samples from Finland, Sweden and the UK.
Figure 4. Comparison of homologs of the human MAMDC1 protein. Alignment of MAMDC1 full-length polypeptide with other proteins
containing identical structural domains (reported on the left: MAM, meprin/A5-protein/PTPmu; FNIII, fibronectin, type III-like fold, Ig-like,
immunoglobulin-like; EGF, epidermal growth factor; MATH/TRAF, meprin and TRAF-C homology/TNF-receptor associated factor; FV/FVIII, coagulation
factor V/VIII; CUB, complement C1r/C1s, Uegf, Bmp1). The branching diagram (cladogram) was generated by multiple sequence alignment of the
protein sequences using ClustalW [60].
doi:10.1371/journal.pone.0008037.g004
MAMDC1 and SLE Susceptibility
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There are 2317 SNPs contained within MAMDC1, which covers
a region of 0.8 megabases (Mb) and several linkage disequilibrium
(LD) blocks (not shown). Based on the moderate effect ofMAMDC1
on SLE susceptibility, it is unlikely that this gene would appear
among the top findings reported in any of the GWAs studies.
Recently, MAMDC1 was also found associated with neuroticism
in a GWA study followed by a replication in an independent
sample set [34]. Four SNPs in MAMDC1, all located in a 39 37 kb
region of high LD including the 10th exon, showed P-values of
1026 to 1025 in the GWA study sample and of 0.006 to 0.02 in the
replication sample. However, this finding could not be supported
in a follow-up association study [35]. Neuroticism is a trait that
reflects a tendency toward negative mood states [36] and is linked
to internalizing psychiatric conditions, such as anxiety and
depression [37,38]. With regard to SLE, this finding is of
relevance since neuropsychiatric manifestations are among the
ACR criteria used in the diagnosis of SLE. Furthermore, and of
potential interest, exonic copy number variants in MAMDC1 was
recently shown to contribute to risk in autism spectrum disorders
[39]. Unfortunately we do not have sufficient power to test for
association between MAMDC1 and different SLE neuropsychiatric
manifestations.
The expression and function of the MAMDC1 gene and protein
are not well studied: besides showing expression in the rat brain
and suggested to have a role in axon guidance [28], not much is
known. We report here for the first time that the MAMDC1 gene
and protein were expressed in several tissues in humans, including
the immune system. We could further show that MAMDC1
mRNA is up-regulated by pro-inflammatory cytokines. Similar to
previous observations made for other members of the IgCAM
superfamily, such as intercellular adhesion molecule-1 (ICAM-1
[MIM 147840]) and vascular cell adhesion molecule-1 (VCAM-1
[MIM 192225]) [40–43], these results suggest that MAMDC1
expression could increase during inflammation, and it is tempting
to speculate that its potential role in SLE might be related to the
dysregulation of immune functions typical of this disease.
Migration of leukocytes to sites of inflammation is crucial to the
pathogenesis and development of inflammatory lesions in SLE and
other autoimmune disorders [44]. Although the mechanisms
underlying this leukocyte redistribution are still not fully
understood, adhesion molecules such as those of the IgCAM
superfamily have been strongly implicated in the recruitment of
immune cells to sites of inflammation, and changes in their
expression have been reported in rheumatoid arthritis (MIM
180300), multiple sclerosis (MIM 126200), insulin-dependent
diabetes mellitus (MIM 222100), and SLE [45,46]. Increased
expression of VCAM-1 and ICAM-1 has been shown in SLE
tissues such as the skin [43] and heart [40] and high levels of
VCAM-1, associated with enhanced systemic TNF-a activity, was
recently demonstrated to characterize SLE patients with manifest
cardiovascular disease [47]. Given its putative function as an
adhesion molecule, MAMDC1 might act through similar
mechanisms, and it is possible that genetic alterations of its
expression or function might have an impact on SLE disease
predisposition and/or manifestations. Remarkably, a similar
scenario has been proposed for the new SLE susceptibility gene
ITGAM (MIM 120980), recently identified in two parallel GWA
studies [12,13]. It codes for an adhesion molecule interacting,
among others, with ICAM-1 to slow down leukocyte rolling and
migration to inflammatory sites [48]. Inspired by the functional
similarity between MAMDC1 and ITGAM, we performed a
preliminary analysis of their potential interaction, by using
genotyping data available (unpublished and refs [13] and [49])
for MAMDC1 SNPs rs961616 and rs2297926 (in the entire sample
set), and for ITGAM SNPs rs11150614 and rs11574637 (respec-
tively in the UK sample, and in the Finnish and Swedish sample
sets). A multivariate logistic regression analysis, however, did not
disclose any significant interaction (data not shown).
Figure 5. Analysis of MAMDC1 mRNA expression. Northern blot analysis of MAMDC1 mRNA expression in different human tissues, showing
several expressed splice variants. MAMDC1 mRNA transcript corresponding to the full-length isoform is indicated by an arrowhead on the right side. A
b-Actin cDNA control probe was used for normalization (bottom).
doi:10.1371/journal.pone.0008037.g005
MAMDC1 and SLE Susceptibility
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In conclusion, we have shown here that MAMDC1 polymor-
phism associates to SLE susceptibility in four sets of patients and
controls from Finland, Sweden and the UK. Similar to
homologous members of the IgCAM superfamily, the encoded
protein has a predicted role in cellular adhesion and migration.
While functional polymorphisms are yet to be identified, our data
should stimulate further studies to fully appraise the role of
MAMDC1 in SLE. Moreover, genetic and/or functional analyses
of its interaction(s) with novel SLE predisposing genes might hold
potential for the discovery of new pathogenetic pathways.
Materials and Methods
Subjects and Samples
Ethics statement. Studies on ‘‘Identification of genes
predisposing for Systemic Lupus Erythematosus (SLE)’’ has been
approved to Professor Juha Kere by the Karolinska Institutet
Research Ethics committee South at Huddinge University hospital
F59 (Dnr 45/03).
Finnish sample sets. The original Finnish family cohort
consist of 192 families (of which 86 were multiply affected by SLE),
including 236 individuals affected with SLE and their healthy
relatives. All SLE patients included in this cohort were interviewed
by the same physician and the case records from the hospitals were
reviewed [50]. All patients met the American College of
Rheumatology (ACR) criteria for the diagnosis of SLE [37]. A
subset of this material, including 35 multiplex families and 31
simplex families, all informative for linkage, was used for the
identification and fine mapping of the 14q11.2-q23.2 locus
[16,17].
The Finnish case-control cohort consists of 86 SLE cases and
356 controls from Finland. For the collection of this material, all
patients with clinical diagnosis of and SLE attending the
Departments of Dermatology at Helsinki and Tampere University
Central Hospitals during 1995–2005 were identified from the
corresponding hospital registries, and contacted by mail or phone
[51]. Unaffected unrelated family members (spouses or common-
law spouses) were asked to participate in the study as control
individuals, and an existing collection of unrelated individuals was
also used as control. The participating patients were clinically
examined by doctors working at the Department of Dermatology
(SK, TH, JP) and interviewed using a structured questionnaire
[51]. The diagnosis of SLE had also been verified by a
rheumatologist.
UK sample set. The UK family cohort consists of 365 SLE
parent affected trios and in this collection, diagnosis of SLE was
established by telephone interview, health questionnaire and
details from clinical notes [52]. All collected probands conformed
to the ACR criteria for SLE [53].
Swedish sample set. The Swedish case-control cohort
consists of 304 cases and 307 controls. All patients were inter-
viewed and examined by a rheumatologist at the Department of
Rheumatology, Karolinska University Hospital and all fulfilled
four or more of the American College of Rheumatology (ACR)
Figure 6. Analysis of MAMDC1 protein expression. IHC analysis of MAMDC1 protein expression in A) testis, showing positive staining in Leydig
cells; B) testis, negative control; C) placenta, showing positive staining in syncytial trophoblasts (arrows); D) positive duodenal villi; E) kidney, positive
staining observed in occasional glomerular neutrophils; F) kidney, negative control; G) SLE skin with positive staining in the upper dermis in the same
region as elastic fibres; H) SLE skin stained with Weigert’s Resorcin-Fuchsin, detecting elastic fibers: arrows in G and H mark corresponding regions I)
Cutaneous squamous cell cancer, with positive staining in neutrophils. Scale bars: 5 mm (A, B, G, H), 2.5 mm (C, D, I), 1.6 mm (E, F).
doi:10.1371/journal.pone.0008037.g006
MAMDC1 and SLE Susceptibility
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1982 revised classification criteria for SLE [54]. The control
samples were collected from population-based control individuals
individually matched for age and sex with the patients.
The demographic and clinical characteristics of the study
populations have in part been previously described [50–52,54] and
are reported in Table S3. All participants included in the present
study gave written informed consent for participation in genetic
studies on SLE and the study protocols were reviewed and
approved by the local ethical committees.
Genotyping
Selection of MS markers has been previously described [16,17].
The SNPs were selected from dbSNP based on availability and their
informativeness as of at the time the study was begun (information
regarding tagging properties were limited at the time of SNP
selection), with a preference for validated markers with a minor
allele frequency (MAF) of .0.2. SNP positions are presented
according to their location in the NCBI dbSNP Build 128.
All genotyping was performed at the Mutation Analysis Facility
(MAF) at Karolinska Institutet, Huddinge, Sweden (www.maf.ki.
se) using the Molecular Dynamics MegaBACE 1000 system
(Global Medical Instrumentation, Albertville, MN, USA) for MS
genotyping, and matrix-assisted laser desorption/ionization time-
of-flight (MALDI-TOF) mass spectrometry based on allele-specific
primer extension with either MassEXTENDH (hME) or iPLEX
methods [55] (Sequenom Inc., San Diego, California, USA, www.
sequenom.com), for SNP genotyping. PedCheck [56] was used to
detect Mendelian inconsistencies, and markers deviating .10%
than expected were excluded from the analysis. Hardy-Weinberg
calculations were performed in controls to ensure that each marker
was in equilibrium.
Northern Blot
A pCMV6-XL4 vector containing a sequence identical to
MAMDC1 NCBI database entry AY369208.1 was purchased from
OriGene Technologies (Rockville, MD, USA) and entirely
sequenced, identifying an additional 108 bp of 59 untranslated
region (UTR) from MAMDC1 exon 1a, and a G to T nucleotide
change in exon 9 (corresponding to the SNP rs12590500). The
MAMDC1 full-length cDNA was excised from the vector using Not
1 restriction digesion (New England Biolabs, Ipswich, MA, USA)
and gel purified. Fifty nano grams (ng) of purified cDNA were then
labelled with P32-dCTP (GE Healthcare, Buckinghamshire, UK)
by random priming and was used to probe two human multiple
tissue polyA+ RNA Northern blots (HB2010 and HB2011,
OriGene Technologies) according to manufacturer’s instructions.
Twenty five ng of b-Actin cDNA control probe were used for
normalization (OriGene Technologies). Exposure to Hyperfilm
MP (GE Healthcare) was done for three days.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections from testis
(n = 2), kidney (n= 1), duodenum (n= 2), placenta (n = 2),
cutaneous squamous cell carcinoma (n= 4), and SLE skin (n = 9),
were obtained from the Departments of Pathology and Derma-
topathology, Helsinki University Central Hospital, Finland. The
SLE diagnoses were based on clinical and laboratory data (SK),
and confirmed histologically by an experienced dermatopatholo-
gist. The use of archived paraffin-embedded material was
approved by the corresponding Ethical Review Board of the
Helsinki University Central Hospital, Finland.
IHC analysis was performed using the peroxidase-conjugated
EnVision+ peroxidase technique (Dual Link System, Peroxidase,
DakoCytomation, Glostrup, Denmark), with diaminobenzidine
(DAB) as chromogenic substrate and Mayer hematoxylin as
counterstain. Incubation with primary rabbit polyclonal antibody
(1:20, HPA003084, Atlas Antibodies, Stockholm, Sweden), in PBS
containing 1% bovine serum albumin (BSA, Sigma-Aldrich), was
performed for 30 min at room temperature. Rabbit immunoglob-
ulin G serum (1:20, Zymed Laboratories Inc., South San
Francisco, CA, USA) or 1% BSA in PBS was used as a negative
control.
Immunohistochemical specimens were analyzed by three
different investigators (TMJ, US-K, A R-S) under a light
microscope at 2006magnification. Staining of 10 or more cells
was interpreted as positive result.
THP-1 Cell Stimulations
THP-1 monocytes were plated on 6-well-plates (1.46106 cells/
well) and grown overnight in RPMI 1640 medium (GIBCO
Invitrogen Life Technologies, Paisley, Scotland) supplemented
with 10% FCS, 1 mM sodium pyruvate, 10 mM HEPES, 100 U
of penicillin, 100 mg/ml streptomycin and 0.05 mM b-mercapto-
ethanol. The cells were then treated with 1mg/ml LPS (Sigma, St.
Louis, MO, USA), 10 ng/ml TGF-b1 (Sigma), 5 U/ml IL-1b
(Roche Molecular Biochemicals, Indiananpolis, IN, USA), 10 ng/
ml IFN-c (Sigma), 50 ng/ml TNF-a (Sigma), or a combination of
TNF-a and IFN-c. Stimulation was allowed to proceed for 6 and
Figure 7. Effect of selected cytokines on MAMDC1 mRNA
expression in THP-1 monocytes. THP-1 cells were treated for 24 h
with LPS, TGF-b1, IL-1b, IFN-c, TNF-a, or a combination of TNF-a and
IFN-c, and MAMDC1 mRNA expression was quantified by Real-Time PCR
in triplicate experiments. The results are reported as fold changes
relative to THP-1 cells grown in the absence of stimulation (control),
with the smallest observation, lower quartile, median, upper quartile,
and largest observation shown for each sample.
doi:10.1371/journal.pone.0008037.g007
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24 h. All experiments were carried out in triplicate and cells grown
in normal medium were used as controls.
Quantitative qRT-PCR
Total RNA was extracted from lysed cells using the RNeasy
Mini-kit (QIAGEN Inc, Hilden, Germany) and reverse tran-
scribed to cDNA using SuperScriptTM III Reverse Transcriptase
reagents (Invitrogen, Carlsbad, CA, USA), according to manu-
facturers’ instructions.
Primers specific to the MAMDC1 full-length isoform 1 (forward:
59-GATCTCTGGCCAAGGAGTGT-39; reverse: 59-GCCTGA-
GTGCACAATACGAA-39) were designed with the Primer
Express 2.0 software (Applied Biosystems, Foster City, CA,
USA). Quantitative qRT-PCR reactions, with cDNA as template,
were performed in triplicates with the 7500 Fast Real-Time PCR
system using SYBR green chemistry and standard protocols
(Applied Biosystems).
After normalization to the endogenous housekeeping gene
GAPDH, MAMDC1 level of expression in each sample was
determined by the comparative CT method of relative quantifi-
cation, and expressed in arbitrary units relative to a randomly
chosen reference sample or to unstimulated cells.
Statistics
The disease association was initially mined by Haplotype
Pattern Mining (HPM, 50,000 permutations) [22] and Pedigree
Disequilibrium test (PDT) [21]. HPM is a method based on
discovering recurrent marker patterns and has been shown to be
robust and powerful for sparse marker maps. PDT integrates
extended families information into the more traditional Trans-
mission Disequilibrium Test.
Single marker association for the fine mapping stage was
analyzed using two different methods; PDTPHASE in the family
cohorts and COCAPHASE in the case control cohorts [21].
Meta-analysis of the case control and family data was performed
using the Kazeem and Farrell [57] fixed effect model implemented
in the R package catmap1.5 [www.r-project.org]. Heterogeneity
was assessed using a standard Q- test.
To take into account multiple testing in the fine mapping step,
the nominal significance threshold of P=0.05 was corrected by
finding the number of independent SNPs, using a Principal
Component Analysis of the SNPs correlation matrix [58]. Out of
the 24 markers genotyped in this study, 16 resulted to be
statistically independent, which fixed the significance threshold to
P=0.0032.
Haplotypes were tested using ‘‘haplo.stats 1.3.0’’ software from
R. Here, haplotype inference is performed with a standard
Expectation Maximization method and the association is tested
with a Generalized Linear Model, which uses haplotypes posterior
probabilities as weights. Haplotypes were tested over blocks of
consecutive markers as defined in Haploview 4.1 (http://www.
broad.mit.edu/mpg/haploview) [59].
Web Resources
NCBI (http://www.ncbi.nlm.nih.gov/)
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/)
Online Mendelian Inheritance in Man (OMIM) (http://www.
ncbi.nih.gov/entrez/query.fcgi?db =OMIM)
Primer3 (http://frodo.wi.mit.edu/primer3/primer3_code.html)
SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/)
Swedish Human Protein Atlas program (www.proteinatals.org)
Mutation Analysis Facility (MAF) at Karolinska Institutet,
Stockholm, Sweden (www.maf.ki.se)
Sequenom Inc. (www.sequenom.com)
Haploview 4.1 (http://www.broad.mit.edu/mpg/haploview)
R (www.r-project.org)
ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/index.html)
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Found at: doi:10.1371/journal.pone.0008037.s001 (0.14 MB
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Table S2 P-values and ORs for the combined analysis
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